ArticleiScience2023
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults.
Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- A longitudinal study of antibody responses to endemic HCoV and novel SARS-CoV-2 among mother-child pairs in Zambia.BMC infectious diseases · 2025Article
- Pulmonary and Immune Dysfunction in Pediatric Long COVID: A Case Study Evaluating the Utility of ChatGPT-4 for Analyzing Scientific Articles.Journal of clinical medicine · 2025Review
- SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.Nature communications · 2025Article
- SARS-CoV-2 Infection in Children: Revisiting Host-Virus Interactions Through Post-Infection Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
- Humoral and Cellular Immune Responses to SARS-CoV-2 in Participants with Head and Neck Cancer.Viruses · 2025Article
- Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection.Viruses · 2025Article
- SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annual review of immunology · 2025Review
- Methods for Modeling Early Life Stress in Rodents.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Kinetics and Durability of Antibody and T-Cell Responses to SARS-CoV-2 in Children.The Journal of infectious diseases · 2024Article
- Understanding antibody magnitude and durability following vaccination against SARS-CoV-2.Mathematical biosciences · 2024Article
- Durability of immune responses to SARS-CoV-2 infection and vaccination.Seminars in immunology · 2024Review
- Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting.PloS one · 2024Article
- Variant-specific antibody profiling for tracking SARS-CoV-2 variant infections in children and adolescents.Frontiers in immunology · 2024Article
- SARS-CoV-2 anti-RBD and anti-N protein responses are differentially regulated between mother-child pairs: insight from a national study cohort at the Faroe Islands.Frontiers in immunology · 2024Article
- Immunogenicity of the CoronaVac vaccine in children: a real-world study.Frontiers in immunology · 2024Article
- Routine Surveillance of SARS-CoV-2 Serostatus in Pediatrics Allows Monitoring of Humoral Response.Microorganisms · 2023Article
- Article
Corrections and comments
- Update of
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
As SARS-CoV-2 becomes endemic, it is critical to understand immunity following early-life infection. We evaluated humoral responses to SARS-CoV-2 in 23 infants/young children. Antibody responses to SARS-CoV-2 spike antigens peaked approximately 30 days after infection and were maintained up to 500 days with little apparent decay. While the magnitude of humoral responses was similar to an adult cohort recovered from mild/moderate COVID-19, both binding and neutralization titers to WT SARS-CoV-2 were more durable in infants/young children, with spike and RBD IgG antibody half-life nearly 4X as long as in adults. IgG subtype analysis revealed that while IgG1 formed the majority of the response in both groups, IgG3 was more common in adults and IgG2 in infants/young children. These findings raise important questions regarding differential regulation of humoral immunity in infants/young children and adults and could have broad implications for the timing of vaccination and booster strategies in this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.